Republic of Korea

Population 2018: 51 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>34 (31–36)</td>
<td>66 (61–71)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.32 (0.18–0.51)</td>
<td>0.63 (0.36–0.99)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>1.5 (1.3–1.7)</td>
<td>2.9 (2.6–3.3)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>2.4 (2.3–2.5)</td>
<td>4.7 (4.4–4.9)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.035 (0.014–0.065)</td>
<td>0.07 (0.03–0.13)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 3.2% (2.9–3.5)
- Previously treated cases: 9.2% (8.2–10)

#### TB case notifications, 2018

- Total new and relapse: 31,534
- % tested with rapid diagnostics at time of diagnosis: 26%
- % with known HIV status: 80%
- % pulmonary: 78%
- % children aged 0–14 years: 40%
- % women: 60%

#### TB/HIV care in new and relapse TB patients, 2018

- % patients with known HIV status who are HIV-positive: 7%
- % on antiretroviral therapy: 85%

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance:
  - New cases: 85%
  - Previously treated cases: 82%
- Laboratory-confirmed cases: MDR/RR-TB: 785, XDR-TB: 29
- Patients started on treatment: MDR/RR-TB: 794, XDR-TB: 29
- MDR/RR-TB cases tested for resistance to second-line drugs: 738

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2017</td>
<td>83%</td>
<td>31,699</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2017</td>
<td>68%</td>
<td>2,919</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
<td>66%</td>
<td>852</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2016</td>
<td>58%</td>
<td>36</td>
</tr>
</tbody>
</table>

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 60% (46–93)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 60% (46–93)

#### TB financing, 2019

- National TB budget (US$ millions): 55
- Funding source: 100% domestic, international, 0% unfunded

---

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-20

Data: www.who.int/tb/data